AbbVie Receives FDA Approval For SKYRIZI For The Treatment Of Children Six Years Of Age And Older With Moderate-To-Severe Plaque Psoriasis Who Are Candidates For Systemic Therapy Or Phototherapy, Or Active Psoriatic Arthritis

Loading news article.

AbbVie Receives FDA Approval For SKYRIZI For The Treatment Of Children Six Years Of Age And Older With Moderate-To-Severe Plaque Psoriasis Who Are Candidates For Systemic Therapy Or Phototherapy, Or Active Psoriatic Arthritis | WAPE

AbbVie Receives FDA Approval For SKYRIZI For The Treatment Of Children Six Years Of Age And Older With Moderate-To-Severe Plaque Psoriasis Who Are Candidates For Systemic Therapy Or Phototherapy, Or Active Psoriatic Arthritis

Article summary

Related companies

Comments —